

# 7<sup>TH</sup> DRESDEN SYMPOSIUM ON AUTOANTIBODIES

DRESDEN, SEPTEMBER 1–4, 2004



## FINAL PROGRAMME



22th June 2004, a historical day for Dresden:

The reconstruction of the "Church of our Lady" is finished by the setup of the church spire.

*(Picture: Bernd Bierwolf)*

Dear Colleagues,

On behalf of the organizers, the Medical Faculty of the Technical University Dresden and the "Gesellschaft zur Förderung der Immundiagnostik e.V." (Society for the Advancement of Immune Diagnostics), I am honoured and pleased to welcome you to the 7<sup>th</sup> Dresden Symposium on Autoantibodies.

The revolutionary techniques of modern molecular and cellular biology enhance almost daily our knowledge of immunity and autoimmunity in men and experimental animals. Our fragmentary puzzle of the immune system is going to form a fascinating picture of a master piece of evolution. Although many of these aspects were achieved by analysis of human body fluids and tissues, the etiopathogenesis of autoimmune diseases cannot readily be analyzed without appropriate animal models. Therefore it is not a surprise that the current Dresden meeting on autoantibodies entitled "From Animal Models to Human Genetics – Research on the Induction and Pathogenicity of Autoantibodies" will focus on experimental autoimmune models. In 12 sessions we will have the opportunity to hear and discuss about the pathogenesis and therapy of autoimmunity in experimental mouse models, natural and pathogenic autoantibodies, molecular mechanisms of xenobiotic-induced autoimmunity as well as the genetic background of autoimmune diseases. We will extend our current knowledge about novel autoantibodies and their pathogenic and/or clinical relevance, autoantibodies in systemic and neurological diseases, the occurrence and measurement of therapy-induced antibodies, and methodical aspects as well as novel diagnostic strategies including multiplex assays for autoantibody profiling.

Since the last symposium many exciting changes were happened in Dresden. The vast damages of the once-in-a-thousand-years flood of 2002 are completely eliminated also due to the nationwide and international help. But the most important change you will find in the skyline of Dresden: The famous "Church of our Lady", destructed in 1945, has been reconstructed. So the habitants and the visitors can enjoy again the view of the historical skyline of Dresden which already has inspired the famous italian painter Canaletto, therefore named "the Canaletto view".

I am very grateful to all participants for their active contribution. I express my gratitude towards all organisers and sponsors who made this symposium possible. We will do our best to make the 7<sup>th</sup> Dresden Symposium on Autoantibodies an unforgettable event.

Karsten Conrad

WEDNESDAY  
SEPTEMBER 1

08.30–10.15

**Registration**

10.15–10.30

**Welcome and Introductions**

10.30–11.15

**PLENARY LECTURE:**

**Autoimmunity in systemic diseases: Past, present and future**

*M. Reichlin (Oklahoma City, USA)*

11.15–11.45

COFFEE BREAK

11.45–13.15

**ANIMAL MODELS I**

Co-Chairs: W.H. Reeves (Gainesville, USA)

Y. Shoenfeld (Tel Hashomer, Israel)

**Main Lectures**

11.45–12.25

Novel autoimmune models: Lessons from recent transgenic and knock in animals

*M.P. Bachmann (Dresden, Germany)*

12.25–13.05

Role of long-lived autoreactive plasma cells in autoimmunity

*F. Hiepe (Berlin, Germany)*

13.05–13.15

**Short Lecture**

**P1**

The role of proinflammatory stimuli in the pathogenesis of MPO-ANCA associated vasculitis in a mouse model using MPO-deficient mice

*D. Huugen, H. Xiao, A. van Esch, C.J. Peutz-Kootstra, J.C. Jennette, J.W. Cohen Tervaert, P. Heeringa (Maastricht, The Netherlands)*

13.15–14.15

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

**Poster Session (P2–6)**

Chair: M.P. Bachmann (Dresden, Germany)

**P2** Syngeneic cells in late apoptosis mature DC in vivo and induce antibodies to dsDNA and neo-epitopes of La/SS-B in immunized mice

*P. Zi-jian, K. Davis, S. Maier, J. Workman, M.P. Bachmann, A.D. Farris (Oklahoma City, USA)*

**P3** Rheumatic Fever: an animal model for a human disease  
*F.F. Alcantara, E. Postol, E.R. Alencar, J. Kalil, L. Guilherme (Sao Paulo, Brazil)*

**P4** Binding properties of a sequence-specific pathogenic Lupus anti-ssDNA autoantibody  
*M. Bobeck, J. Cleary, G.D. Glick (Ann Arbor, USA)*

**P5** IgM anti-dsDNA antibodies as a treatment of murine systemic Lupus erythematosus (SLE)  
*S. Werwitzke, D. Trick, K. Kamino, T. Matthias, K. Kniesch, B. Schlegelberger, R.E. Schmidt, T. Witte (Hannover, Germany)*

**P6** Peptide mimetics of anti-dsDNA idiotypes as a tool for Lupus-specific IVIG preparation: Specificity and efficacy in the treatment of experimental SLE  
*M. Blank, I. Nur, R. Meidler, L. Bar, L. Slutzki, B. Gilburd, Y. Shoenfeld (Tel Hashomer, Israel)*

**ANIMAL MODELS II**

Co-Chairs: M.P. Bachmann (Dresden, Germany)  
F. Hiepe (Berlin, Germany)

**Main Lectures**

Innate immunity and interferon production in the pathogenesis of autoantibodies in lupus  
*W.H. Reeves (Gainesville, USA)*

Autoantibodies – predictive, pathogenic and protective  
*Y. Shoenfeld (Tel Hashomer, Israel)*

**Short Lectures**

- 15.35–15.45 **P7** Selective suppression of DNA-specific B cells in lupus mice by a chimeric antibody/peptide molecule  
*A. Tchorbanov, E. Voynova, N. Mihailova, T. Vassilev (Sofia, Bulgaria)*
- 15.45–15.55 **P8** Demonstration of humoral autoimmunity in the tight skin-2 mouse: a model for systemic sclerosis  
*J. Gentiletti, S.A. Jimenez, P. Christner (Philadelphia, USA)*
- 15.55–16.05 **P9** Pathogenicity of autoantibodies reactive with the endogenous retroviral envelope glycoprotein gp70  
*M. Miyazawa, E. Kajiwara, N. Tabata, T. Ogawa, T. Yuasa, H. Matsumura (Osaka, Japan)*
- 16.05–16.15 **P10** Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia  
*A. Musaji, M. Meite, L. Detalle, S. Franquin, F. Cormont, V. Préat, S. Izui, J.-P. Coutelier (Bruxelles, Belgium)*
- 16.15–16.45 COFFEE BREAK – POSTER AND EXHIBITION VIEWING
- 16.45–18.00** **NATURAL AND PATHOGENIC AUTOANTIBODIES**  
Co-Chairs: P.L. Meroni (Milano, Italy)  
A. Kromminga (Hamburg, Germany)

**Main Lectures**

- 16.45–17.20 Beneficial aspects of natural autoantibodies  
*S.V. Kaveri (Paris, France)*
- 17.20–17.55 Disease idiotype specific IVIG – Novel therapeutical approach  
*Y. Shoenfeld (Tel Hashomer, Israel)*
- 17.55–18.30 Receptors of the innate immunity as targets for circulating autoantibodies: antiphospholipid syndrome as a paradigm  
*P.L. Meroni (Milano, Italy)*

**Short Lecture**

**P11** Catalytically active antibodies in patients with autoimmune diseases

*G.A. Nevinsky (Novosibirsk, Russia)*

18.30–18.40

**Welcome Reception**

19.00

09.00–10.30

**MOLECULAR MECHANISMS OF XENOBIOTIC-INDUCED AUTOIMMUNITY**

Co-Chairs: P. Hultman (Linköping, Sweden)  
H. Schellekens (Utrecht, The Netherlands)

**Main Lectures**

09.00–09.40 Immunology and genetics of xenobiotic-induced autoimmunity  
*K.M. Pollard (La Jolla, USA)*

09.40–10.20 Xenobiotic-induced autoimmune responses and protein aggregation diseases share a common subnuclear pathology  
*A. von Mikecz (Düsseldorf, Germany)*

10.20–11.00 COFFEE BREAK – POSTER AND EXHIBITION VIEWING

10.30–11.00 **Poster Session (P12–16)**

Chair: K.M. Pollard (La Jolla, USA)

**P12** Proteasomal-dependent antigen processing of topoisomerase I in scleroderma  
*M. Chen, A. Tanbajewa, A. Kuhn, T. Ruzicka, A. von Mikecz (Düsseldorf, Germany)*

**P13** The immunotoxin mercury chloride induces specific alterations in the cell nucleus  
*A. Scharf, M. Chen, A. von Mikecz (Düsseldorf, Germany)*

**P14** Exposure to the organic mercury compound thimerosal leads to immunosuppression followed by systemic autoimmunity  
*S. Havarinasab, B. Häggqvist, E. Björn, K.M. Pollard, P. Hultman (Linköping, Sweden)*

**P15** The importance of Fc-receptors in mercury-induced autoimmunity  
*K. Martinsson, P. Hultman (Linköping, Sweden)*

**P16** An autoimmune response to tyrosine-nitrated autologous IgG: immunogenicity of a self protein bearing the inflammation-associated marker  
*H. Ohmori, M. Oka, H. Shigemitsu, Y. Nishikawa, M. Takeuchi, M. Magari, N. Kanayama (Okayama, Japan)*



**GENETIC FACTORS AND AUTOIMMUNITY**

Co-Chairs: Y. Shoenfeld (Tel Hashomer, Israel)  
W.J. van Venrooij (Nijmegen, The Netherlands)

**Main Lectures**

Genetic predispositions of autoimmune diseases  
*J.B. Harley (Oklahoma City, USA)* 11.00–11.40

Identification of peptidyl arginine deiminase type 4 as a  
rheumatoid arthritis-associated gene  
*R. Yamada (Yokohama City, Japan)* 12.20–12.30

**Short Lecture**

**P17** Gene identification of single chain format variable  
(scFv) anti- $\beta$ 2-Glycoprotein-I (a $\beta$ 2GP-I) and anti-prothrom-  
bin (aPt) antibodies obtained from a primary anti-phospho-  
lipid syndrome (PAPS) patient by phage display  
*J. Cabiedes, M. Languren, B. Becerril, L.E. Fernández-Altuna, V.  
Pascual, D. Alarcón-Segovia, A.R. Cabral (Mexico City, Mexico)* 12.30–12.45

LUNCH BREAK – POSTER AND EXHIBITION VIEWING 12.30–13.30

**Poster Session**

**Genetic Susceptibility and Pathogenesis  
(P18–21)**

Chair: M.P. Bachmann 13.00–13.30

**P18** The contribution of Fc $\gamma$ R11A and interleukin 10 (IL-10)  
gene promoter polymorphisms to genetic susceptibility of  
systemic lupus erythematosus (SLE) and lupus nephritis in  
Russian population  
*I. Guseva, A. Gelonkina, E. Luchihina, M. Ivanova, V.  
Myakotkin (Moscow, Russia)*

**P19** Anti-cyclic citrullinated peptide antibody production  
in rheumatoid arthritis is controlled by HLA-DRB1  
*I. Senkpiehl, M. Marget, M. Wedler, S. Jenisch, J. Georgi, D.  
Kabelitz, J. Steinmann (Kiel, Germany)*

**P20** Exploring the role of caspase-3 in human dermal endothelial cell apoptosis induced by scleroderma serum  
*S. Ahmed (Boston, USA)*

**P21** CD11c high expressing dendritic cells (DCs) are upregulated in SLE  
*V. Gerl, P. Großmann, D. Panne, M. Gerl, A. Waka, B. Hostmann, K. Reiter, J. Kaufmann, A. Jacobi, T. Alexander, A. Radbruch, F. Hiepe (Berlin, Germany)*

13.30–15.20

**NOVEL AUTOANTIBODIES OF PATHOGENETIC AND/OR CLINICAL RELEVANCE I**

Co-Chairs: M. Fritzler (Calgary, Canada)  
E. Matsuura (Okayama, Japan)

**Main Lectures**

13.30–14.10

Autoantibody target GW bodies – cytoplasmic foci of mRNA decay and regulatory functions  
*E.K.L. Chan (Gainesville, USA)*

14.10–14.40

Some considerations about structure, function and pathogenicity of Ro ribonucleoproteins  
*G. Steiner (Vienna, Austria)*

14.40–15.20

Autoantibodies to the LEDGF (DFS70) autoantigen: what are they telling us?  
*C. Casiano (Loma Linda, USA)*

15.20–16.00

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

15.40–16.00

**Poster Session (P22–24)**

Chair: E.K.L. Chan (Gainesville, USA)

**P22** False-positive perinuclear antineutrophil cytoplasmic antibody (P-ANCA) in hemodialysis patients and analysis of their target antigens  
*T. Uchimura, S. Yamada, K. Inoue, Y. Motomiya, T. Hashiguchi, I. Maruyama (Kagoshima City, Japan)*

**P23** Clinical correlations of anti-CENP-F antibodies in a cohort of patients from Southern Spain

*I. Wichmann, R. Magariño, I. Magariño, A. Torres, N. Respaldiza, M. Encarnación, A. Fernández-Suarez, A. Nuñez-Roldán (Sevilla, Spain)*

**P24** Presence of antibodies against GSTT1 (glutathion S-transferase T1) in non-transplanted patients

*I. Wichmann, I. Aguilera, J.M. Sousa, A. Bernardos, J.R. García-Lozano, A. Núñez-Roldán (Sevilla, Spain)*

### HUMORAL AUTOIMMUNITY IN NEUROLOGICAL DISEASES

Co-Chairs: R.L. Humbel (Luxembourg)  
F. Blaes (Giessen, Germany)

16.00–18.00

#### Main Lectures

Role of humoral autoimmunity in demyelinating diseases of the CNS

*T. Ziemssen (Dresden, Germany)*

16.00–16.40

Citrullination of CNS proteins during the development in multiple sclerosis and EAE

*R. Raijmakers (Nijmegen, The Netherlands)*

16.40–17.20

#### Short Lectures

**P25** Anti-glycolipid IgG functionality predicts clinical symptoms in a Guillain-Barré syndrome animal model

*N.M. van Sorge, L.H. van den Berg, M.D. Jansen, J.G.J. van de Winkel, N.Yuki, W-L. van der Pol (Utrecht, The Netherlands)*

17.20–17.30

**P26** Autoantibodies to hnRNP-A1 in neuropsychiatric Lupus and other neurological diseases

*G. Burguera, K. Adolph, A. Förster, G. Riemekasten, G.R. Burmester, K. Skriner (Berlin, Germany)*

17.30–17.40

THURSDAY  
SEPTEMBER 2

17.40–17.50

**P27** Complex regional pain syndrome (M. Sudeck) is associated with autoantibodies against autonomic nervous system structures

*F. Blaes, K. Schmitz, M. Tschernatsch, O. Matz, M. Kaps, M. Bräu (Giessen, Germany)*

17.50–18.00

**P28** Frequencies of anti-MOG IgG autoantibodies in serum and cerebrospinal fluid of patients with multiple sclerosis depend on the nature of the antigen and western blotting assay conditions

*U. Wurster, R.B. Lindert, I. Torens, F. Heidenreich (Hannover, Germany)*

**Poster**

**P29** Association between circulating C1q- and C3d-immune complexes and the course of Alzheimer's disease  
*M. Cojocaru, I.M. Cojocaru, D. Iordanescu (Bucharest, Romania)*

**P30** IgG and IgM antibodies to neurofilaments in patients with multiple sclerosis  
*I.M. Malbohan, A. Bartos, L. Fialová, J. Soukupová, J. Kozeny (Prague, Czech Republic)*

**NOVEL AUTOANTIBODIES OF PATHOGENETIC AND/OR CLINICAL RELEVANCE II**

Co-Chairs: E.K.L. Chan (Gainesville, USA)  
C. Casiano (Loma Linda, USA)

**Main Lectures**

Autoantibodies to mitotic chromosomes and spindle apparatus  
*R.L. Humbel (Luxembourg, Luxembourg)* 09.00–09.30

Anti-laminin-1 autoantibodies in reproductive failure:  
human and animal studies  
*E. Matsuura (Okayama, Japan)* 09.30–10.00

**Short Lectures**

**P31** Elevated anti-serum amyloid component P (SAP) anti-  
bodies in SLE patients correlate with disease activity  
*G. Zandman-Goddard, M. Blank, P. Langevitz, M. Pras,  
Y. Levy, T. Witte, A. Doria, J. Rovensky, Y. Shoenfeld  
(Tel Hashomer, Israel)* 10.00–10.10

**P32** The translational suppressors TIA-1 and TIAR are tar-  
geted by autoantibodies and are overexpressed in inflamed  
skin of lupus patients  
*E. Jimenez-Boj, N. Kedersha, M. Tohidast-Akrad,  
F. Karhofer, G. Stummvoll, C. Zimmermann, E. Höfler,  
S. Hayer, G. Schett, P. Anderson, J. Smolen, G. Steiner  
(Vienna, Austria)* 10.10–10.20

**P33** The 40/38 kDa hnRNP-A3, a component of the mRNA  
transport particle, is a novel autoantigen in patients with  
systemic rheumatic diseases  
*K. Adolph, A. Sternjak, A. Förster, G. Steiner, G.R. Bur-  
mester, K. Skriner (Berlin, Germany)* 10.20–10.30

COFFEE BREAK – POSTER AND EXHIBITION VIEWING 10.30–11.00

11.00–13.00

**AUTOANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES**

Co-Chairs: F. Hiepe (Berlin, Germany)  
G. Steiner (Vienna, Austria)

**Main Lectures**

11.00–11.30

Anti-CCP, a specific marker for early rheumatoid arthritis  
*W.J. van Venrooij (Nijmegen, The Netherlands)*

11.30–12.00

The diagnostic and prognostic significance of autoantibodies in patients with very early rheumatoid arthritis  
*V. Nell (Vienna, Austria)*

12.00–12.30

Atherogenic role of protein-modified oxidized low-density lipoproteins and their autoantibodies  
*E. Matsuura (Okayama, Japan)*

**Short Lectures**

12.30–12.40

**P34** Anti-La (SSB) autoantibodies are strongly associated with internal organ damage in patients with primary Sjögren's syndrome  
*R. Pelck, H. Locht, R. Manthorpe (Copenhagen, Denmark)*

12.40–12.50

**P35** Identification and characterization of a SLE specific SmD3 mimotope peptide  
*M. Mahler, M.J. Fritzler, M. Blüthner (Neuss, Germany)*

12.50–13.00

**P36** Autoimmune sera preferentially recognize the apoptotic 40 kDa fragment of the U1-70K antigen  
*G.J.M. Pruijn, D. Hof, K. Cheung, W.J. van Venrooij, J.M.H. Raats (Nijmegen, The Netherlands)*

13.00–14.30

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

13.30–14.30

**Poster Session (P37–39, 44–46, 49, 52–54, 56, 57)**

Chair P37–49: W. van Venrooij  
(Nijmegen, The Netherlands)

Chair P52–57: P.L. Meroni (Milano, Italy)

**P37** Immunomic analysis of synovial fluid exosomes reveals citrullinated proteins in patients with rheumatoid arthritis

*K. Adolph, F. Schumann, P. Jungblut, G.R. Burmester, K. Skriner (Berlin, Germany)*

**P38** Anti-CCP antibodies may occur in patients with true psoriatic arthritis

*I.E.A. Hoffman, B.V. Cruyssen, H. Zmiereczak, M. Vandenberghe, E. Kruithof, L. De Rycke, D. Baeten, H. Mielants, E.M. Veys, F. De Keyser (Ghent, Belgium)*

**P39** Low prevalence of anti-citrullinated peptide antibodies in polyarticular juvenile idiopathic arthritis

*I.E.A. Hoffman, P. Dewint, S. Rogge, R. Joos, J. Dehoorne, A. Union, E.M. Veys, F. De Keyser, D. Elewaut (Ghent, Belgium)*

**P40** Anti-CCP antibodies: Diagnostic sensitivity in Canterbury health laboratories

*M.B. Spellerberg, K.K. Solanki, P.T Chapman, P.W. Moller, J.L. O'Donnell (Christchurch, New Zealand)*

**P41** Antibodies to recombinant human 60 kDa heat shock protein in sera of patients with juvenile idiopathic arthritis

*I. Hromadnikova, D. Zlacka, H. Nguyen, P. Vavrincova (Prague, Czech Republic)*

**P42** Cell responses to heat shock proteins 60, 65, 70 and synthetic hsp-derived peptides in patients with juvenile idiopathic arthritis

*L. Sedlackova, P. Vavrincova, J. Velek, I. Hromadnikova (Prague, Czech Republic)*

**P43** ANCA and coagulation dysfunction in patients with rheumatoid arthritis

*V.V. Bazarny, O.M. Lesnyak, O.V. Berdugina, E.A. Garbovnichaya, N.S. Aphonkina (Ekaterinburg, Russia)*

**P44** The diagnostic and prognostic role of anti-C1q antibodies in SLE

*N. Bizzaro, D. Villalta, E. Tonutti, R. Tozzoli, S. Zampieri, A. Ghirardello, A. Doria (S. Donà di Piave, Italy)*

**P45** Anti-C1q antibodies in Lupus nephritis

*N. Miehle, F. Petschner, B. Nettlenbusch, S. Bartschat-Dominke, U.A. Walker, K. Warnatz, M. Schlesier, H.H. Peter (Freiburg, Germany)*

**P46** TNF-alpha-induced surface expression of 52 kDa Ro/SS-A autoantigen is not sufficient for induction of ADCC in normal human keratinocytes.

*P. Großmann, V. Gerl, C. Johnen, B. Hostmann, K. Bräutigam, N. Toman, F.-W. von Hesler, A. Radbruch, F. Hiepe (Berlin, Germany)*

**P47** Antinuclear and lymphocytotoxic autoantibodies in SLE: does ANA act as lymphocytotoxic antibodies?

*D. Kozáková, V. Bosák, L. Cebecauer, J. Lukác, J. Rovensky (Piestany, Slovak Republic)*

**P48** Thyroid autoantibodies in patients with systemic lupus erythematosus and rheumatoid arthritis

*I. Kostic, R. Petrovic, M. Bukilica, S. Zivancevic-Simonovic (Belgrade, Serbia)*

**P49** PM/Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome

*R. Raijmakers, M. Renz, C. Wiemann, W.V. Egberts, H.P. Seelig, W.J. van Venrooij, G.J.M. Puijn (Nijmegen, The Netherlands)*

**P50** Anti-topoisomerase I (anti-Scl-70) autoantibodies are specific to scleroderma and are not present in patients with SLE

*T. Prestigiacomo, M. Watkins, S.R. Binder (Hercules, USA)*

**P51** Autoantibodies reacting with antigen(s) of the cleavage furrow and the midbody region – specific for patients of the systemic sclerosis spectrum ?

*B. Roch, K. Conrad, U. Kießling, A.K. Menzel, M.P. Bachmann, H.E. Schröder (Dresden, Germany)*

**P52** Anti-a fodrin antibodies in patients with primary Sjögren's syndrome: poor analytical sensitivity or low nosographic prevalence?

*N. Bizzaro, D. Villalta, E. Tonutti, R. Tozzoli (S. Donà di Piave, Italy)*



**P53** Antibodies against 25-mer synthetic peptide of M3 muscarinic acetylcholine receptor in patients with Sjögren's syndrome and SLE

*P. Zigon, S. Cucnik, B. Bozic, B. Rozman, M. Plesivcnik - Novljan, M. Tomsic, T. Kveder (Ljubljana, Slovenia)*

**P54** Autoantibodies against M3 muscarinic acetylcholine receptors in patients with Sjögren's syndrome

*T. Sumida, Y. Naito, E. Wakamatsu, D. Goto, S. Ito, A. Tsutsumi, I. Matsumoto (Tsukuba City, Japan)*

**P55** Patterns of anti-nuclear antibodies (ANA) among patients with primary Sjögren's syndrome with correlation to internal organ affection

*H. Locht, R. Pelck, M. Høier-Madsen, A. Wiik, R. Manthorpe (Malmö, Sweden)*

**P56** Heterogeneous avidity of anti-b2-glycoprotein I antibodies

*S. Cucnik, T. Kveder, B. Rozman, B. Bozic (Ljubljana, Slovenia)*

**P57** Identification of a peptide mimicing the binding pattern of anti-Cardiolipin antibodies

*C. Buschmann, C. Fischer, A. Stachl, K.J. Lackner, P. von Landenberg (Mainz, Germany)*

**P58** The clinical significance of the determination of antiphospholipid antibodies – a retrospective study

*Z. Vanková, K. Malíčková, T. Fucíková, I. Janatková, H. Marecková (Prague, Czech Republic)*

### THERAPY-INDUCED ANTIBODIES

Chair: Srinivasa V. Kaveri (Paris, France)

### Main Lectures

Antibodies to therapeutic proteins: immunization or autoimmunity?

*H. Schellekens (Utrecht, The Netherlands)*

14.30–15.40

14.30–15.00

FRIDAY  
SEPTEMBER 3

15.00–15.30

Heterogeneity of antibody against endogenous and exogenous components

*A. Kromminga (Hamburg, Germany)*

**Short Lecture**

15.30–15.40

**P59** Anti-nuclear antibody profiles during infliximab and etanercept treatment in spondyloarthritis: Is induction of humoral autoimmunity by TNF-alpha blockade a class effect?  
*L. De Rycke, E. Kruithof, F. Van den Bosch, I.E.A Hoffman, E.M. Veys, D. Baeten, F. De Keyser (Ghent, Belgium)*

**Poster**

**P60** Infliximab therapy in Crohn's disease induced autoantibodies restricted to antinuclear and anti-doublestranded DNA autoantibodies without autoimmune clinical manifestations

*E. Blanvillain, B. Parmentier, D. Boucaud-Maitre, S. Nancey, B. Flourié, A. Moreira, J. Bienvenu, N. Fabien (Lyon, France)*

15.40–16.30

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

17.30

**Departure to Pillnitz Castle**

18.30

Guided walking tour

19.30

Social Dinner

**METHODICAL ASPECTS AND DIAGNOSTIC STRATEGIES I**

Co-Chairs: A. Wiik (Copenhagen, Denmark)  
R.L. Humbel (Luxembourg, Luxembourg)

**Main Lectures**

Evaluation of addressable laser bead assays in the detection of autoantibodies

*M. Fritzler (Calgary, Canada)*

08.30–09.10

Autoantibody profiling and B cell characterization using autoantigen and lysate arrays

*P.J. Utz (Stanford, USA)*

09.10–09.50

**Short Lectures**

**P61** Multiplexed analysis of thirteen autoantibodies using the BioPlex™ 2200 fully automated immunoassay analyzer  
*T. Prestigiacomo, R.L. Humbel, B. Larida, S.R. Binder (Hercules, USA)*

09.50–10.00

**P62** Sensitivity and specificity of the FIDIS multiplex immunoassay system for the detection of dsDNA and nuclear specific antibodies in autoimmune rheumatic diseases

*R. Tozzoli, G. Kodermaz, N. Bizzaro, D. Villalta, E. Tonutti, A. Ghirardello, A. Doria (Latisana, Italy)*

10.00–10.10

**P63** Development of a sensitive and reliable biochip for detection of autoantibodies in rheumatic diseases

*W. Schoessler, C. Hentschel, J. Schulte-Pelkum, J. Kreutzberger, F. Hiepe (Berlin, Germany)*

10.10–10.20

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

10.20–11.20

**Poster Session (P68, 70, 71, 78, 83, 85)**

Chair: N. Bizzaro (S. Donà di Piave, Italy)

**P64** Multicentre evaluation of the new multiplex assay FIDIS Connective. Comparison with convencional methods  
*I. Abreu, A. Bastos, C. Cardoso, H. Ribeiro, N. Couceiro, A. Bodas, A.M. Pereira, J. Candeias, J.A.M. Caetano (Lisboa, Portugal)*

**P65** Comparison of two multiplex assays for anti-ENA/ANA determination  
*I. Lochman, A. Kloudova, J. Lupac (Ostrava, Czech Republic)*

**P66** Comparison of different test systems for simultaneous autoantibody detection  
*T. Lüttich, M. Sticherling, D. Scholz, K. Hennig, P. Eißfeller, M. Motz, A. Kromminga (Martinsried, Germany)*

**P67** VIDAS-EDRA: the first automated testing for autoantibodies to citrullinated proteins  
*L. Nogueira, A. Foussadier, A. Constantin, C. Clavel, C. Vincent, A. Cantagrel, M. Jolivet, G. Serre (Toulouse, France)*

**P68** An image inspection system for the automatic classification of Hep-2 cell pattern  
*P. Perner, H. Perner, R. Sonntag (Leipzig, Germany)*

**P69** Results of the European Consensus Finding Study Group on Autoantibodies (March 2003 – March 2004)  
*D. Hamann, P. Charles, M. Renz, H.P. Seelig, A. Wiik, R.J.T. Smeenk (Amsterdam, The Netherlands)*

**P70** The SS-A/Ro 60 kDa protein is sufficient for the detection of autoantibodies against SS-A  
*W. Meyer, T. Scheper, M. Siegemund, K. Takeuchi, W. Schlumberger, W. Stöcker (Lübeck, Germany)*

**P71** The clinical sensitivities and specificities of anti-SSA-52 (Ro-52) and anti-SSA-60 (Ro-60) autoantibodies are dependent on the techniques used to detect them  
*R. Burlingame, A. Piette, C. Peebles, C. von Muhlen, R. Williams, M. Fritzler, P. Charles, K.M. Pollard, N. Fertig, C. Watkins, C. Oddis (San Diego, USA)*

**P72** The optimal anti-dsDNA antibody test strategy for the routine immunological laboratory?

*V. Král, I. Stiborová, D. Jílek (Usti nad Labem, Czech Republic)*

**P73** Autoantibodies in two patients with selective IgM deficiency

*J. Litzman, P. Nemeč, V. Thon, J. Lokaj (Brno, Czech Republic)*

**P74** Diagnostic accuracy of the SmD183-117 antibody immunoassay in SLE

*R. Tozzoli, G. Kodermaz, N. Bizzaro, D. Villalta, E. Tonutti, A. Ghirardello, A. Doria (Latisana, Italy)*

**P75** Improved detection of autoantibodies to the three ribosomal P proteins

*M. Mahler, K. Kessenbrock, M. Szmyrka, P. Höpl, M.J. Fritzler (Neuss, Germany)*

**P76** Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis

*J.G.M.C. Damoiseaux, J. Austen, M.C. Slot, M. Vaessen, C.A. Stegeman, P. van Paassen, J.W. Cohen Tervaert (Maastricht, The Netherlands)*

**P77** A newly developed anti-PR3 Capture ELISA shows a higher correlation to positive cANCA results and a better serological hit rate than a direct anti-PR3 ELISA

*C. Daehrich, W. Schlumberger, C. Lehmann, W. Stöcker (Lübeck, Germany)*

**P78** Diagnosis of goblet cell antibodies in ulcerative colitis by using the cell line HT29-18N2 as antigenic substrate

*L. Komorowski, S. Mindorf, B. Teege, S. Torkler, W. Stöcker (Lübeck, Germany)*

**P79** Anti-intestinal goblet cell antibodies in ulcerative colitis

*M. Cojocar, I.M. Cojocar (Bucharest, Romania)*

**P80** The role of ASCAs in the diagnosis of Crohn's disease: Evidence for a wide variability of commercial methods and for a high prevalence in celiac patients

*E. Tonutti, M. Poletto, D. Visentini, R. Maieron, M. Zilli, N. Bizzaro (Udine, Italy)*

**P81** The autoimmune reactions in patients with inflammatory bowel disease with rheumatic manifestations  
*N. Virstyuk, E. Neyko, M. Orynychak, V. Neyko (Ivano-Frankivsk, Ukraine)*

**P82** Comparison of the diagnostic accuracy of three methods to detect celiac disease  
*M. Stern, A. Patel, G. Blumenstock, T. Mothes, O. Bauer, M. Renz, H.P. Seelig (Karlsruhe, Germany)*

**P83** The diagnostic accuracy of anti-actin antibody detection by immunoblot, ELISA and indirect immunofluorescence methods in patients with autoimmune hepatitis  
*D. Villalta, S. Platzgummer, M. Liguori, M. Tampoia, A. Baragiotta, E. Tonutti, R. Tozzoli, N. Bizzaro (Pordenone, Italy)*

**P84** New ELISA for determination of glutamic acid decarboxylase (GAD65) autoantibodies in type 1 diabetes mellitus  
*C. Krueger, H. Brooking, B.R. Smith, W. Stöcker (Lübeck, Germany)*

**P85** Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics in the general population – The Karlsburg type 1 diabetes risk study  
*M. Schlosser, M. Strebelow, I. Rjasanowski, R. Wassmuth, W. Kerner (Karlsburg, Germany)*

**P86** Heat shock protein 70 (hsp70) antibodies in immunomediated inner ear diseases  
*R. Tozzoli, G. Kodermaz, M. Tampoia, N. Bizzaro, A. Tedesco, D. Villalta, E. Tonutti (Latisana, Italy)*

**P87** The role of anti-IgE autoantibodies in diagnosis of IgE mediated diseases  
*I. Lochman, V. Krauz (Ostrava, Czech Republic)*

**P88** Alteration of autoantibodies against p53 in Taiwanese lung cancer patients undergoing chemotherapy  
*Y.L. Lee, C.M. Shih, H.L. Chiou, M.Y. Shiau, G.C. Chang, Y.H. Chang (Taichung, Taiwan)*

**P89** Autoantibodies against tumor suppressor protein p53 in pleural effusions of patients with tuberculosis pleurisy  
*Y.L. Lee, L. Wang, C.M. Shih, Y.H. Chang, H.L. Chiou, G.H. Shen, M.Y. Shiau (Taichung, Taiwan)*

**P90** Immunological aspect of Perthes' disease and slipped capital femoral epiphysis in children – antiphospholipid antibodies  
*M. Latajski, M. Koziol-Montewka, A. Gregosiewicz, M. Tokarska-Rodak, T. Raganowicz, G. Kandzierski (Lublin, Poland)*

**P91** Cytofluorimetric analysis of apoptosis markers CD95/CD95L (Fas/FasL) in thyroid tissues from young patients with Graves' disease and Hashimoto's thyroiditis  
*A. Bossowski, A. Stasiak-Barmuta, B. Czarnocka, M. Urban, A.P. Weetman, M. Niedziela, E. Korman, J. Dadan (Bialystok, Poland)*

**P92** Heteroimmune reactions at altitudes low and high above sea level  
*R.A. Zulkarneyev (Bishkek, Kyrgyzstan)*

## METHODICAL ASPECTS AND DIAGNOSTIC STRATEGIES II

Co-Chairs: M. Fritzler (Calgary, Canada)  
U. Sack (Leipzig, Germany)

11:20–12.30

### Main Lectures

Cutting edge diagnostics' in rheumatology  
*A. Wiik (Copenhagen, Denmark)*

11.20–11.50

Isotype pattern of autoantibodies  
*R.L. Humbel, N. Wernert (Luxembourg, Luxembourg)*

11.50–12.10

Distinctive features of autoantibodies in normal individuals and in patients with autoimmune diseases  
*L.E.C. Andrade (Sao Paulo, Brazil)*

12.10–12.30

## Venue

The modern Lecture Hall Centre of the Technical University of Dresden is located in the South of the city, about 15 minutes walk away from the Central Railway Station.

Hörsaalzentrum der Technischen Universität Dresden  
Bergstrasse 64, D-01069 Dresden

## Registration office

September 1: 07.30–18.30  
September 2: 08.30–18.30  
September 3: 08.30–18.30  
September 4: 08.30–14.00

## Phone/Fax on site

Phone +49 351 4633 8823  
Fax +49 351 4633 8824

## Chairman

Karsten Conrad, Germany

## Co-Chairmen

Michael P. Bachmann, Germany  
Edward K.L. Chan, USA  
Marvin Fritzler, Canada  
Rene-Louis Humbel, Luxembourg  
Yehuda Shoenfeld, Israel

## International advisory board

Luis E.C. Andrade, Brazil  
Carlos Casiano, USA  
Falk Hiepe, Germany  
Srini V. Kaveri, France  
Arno Kromminga, Germany  
Pier Luigi Meroni, Italy  
K. Michael Pollard, USA  
Westley H. Reeves, USA  
Günter Steiner, Austria  
Walter J. van Venrooij, The Netherlands  
Allan Wiik, Denmark

## Language

English, no simultaneous translation

## City map

see <http://www.advidx.org>



Silke Zwjatkow  
 GFID e.V.  
 Veilchenweg 28  
 D-01326 Dresden  
 Phone +49 351 458 6521  
 Fax +49 351 458 6308  
 e-mail: [streller@rcs.urz.tu-dresden.de](mailto:streller@rcs.urz.tu-dresden.de)

Ulrich Sack  
 Institut für Klinische Immunologie und Transfusionsmedizin  
 Universitätsklinikum Leipzig  
 Johannisallee 30  
 D-04103 Leipzig, GERMANY  
 Phone: +49 341-9725500  
 Fax: +49 341-9725828  
 e-mail: [mail@ulrichsack.de](mailto:mail@ulrichsack.de)

Participants	EUR 350
GFID member	EUR 280
Students/Residents	EUR 180
One day ticket	EUR 120

(includes unlimited access to all scientific sessions, welcome reception, industrial exhibition, 4th volume of the book series "Autoantigens, Autoantibodies, Autoimmunity", coffee and lunch breaks)

**Welcome reception** in the Lecture Hall Centre of the Technical University of Dresden

#### **Guided tour and Social Dinner at Pillnitz Palace**

Pillnitz Palace, the former summer residence of the Saxon royal court is today the home of the Museum of Decorative Arts. The main palace wings were built 1720–1722 for August the Strong (1670–1733), elector of Saxony and king of Poland. The park deserves closer attention as it combines the strict forms of the baroque period with those of an English landscape garden. Before the Social Dinner in the historical Orangery of the Pillnitz Palace we offer a guided walking tour visiting Palace and park. Alongside many rare trees the over 200-year-old Japanese camellia is a particular magnet for visitors. (17.30 Departure by bus)

#### **Organization**

(Registration, Reservation, Exhibition)

#### **Registration fee**

#### **Social programme**

Wednesday,  
 September 1, 2004  
 19.00

Friday,  
 September 3, 2004  
 18.30

The following companies participate in the industrial exhibition and/or have made a generous sponsoring (in alphabetical order):

**A. Menarini Diagnostics Deutschland.**

Eine Zweigniederlassung der Berlin-Chemie  
(Neuss, Germany)

**AID Autoimmun Diagnostika GmbH**

(Straßberg, Germany)

**BIO-RAD Laboratories GmbH**

(München, Germany)

**BioSystems S.A.**

(Barcelona, Spain)

**BMD Biomedical Diagnostics**

(Borken, Germany)

**Bühlmann Laboratories AG**

(Schönenbuch, Switzerland)

**DiaSorin Diagnostics S.p.A.**

(Saluggia, Italy)

**DLD Diagnostika GmbH**

(Hamburg, Germany)

**Duolab Invitrodiagnostika**

(Borken, Germany)

**EUROIMMUN Medizinische Labordiagnostika AG**

(Lübeck, Germany)

**GA Generic Assays GmbH**

(Dahlewitz, Germany)

**IMTEC Immundiagnostika GmbH**

(Berlin, Germany)

**Immundiagnostik AG**  
(Bensheim, Germany)

**Inova Diagnostics, Inc.**  
(San Diego, USA)

**MAST DIAGNOSTICA Laboratoriums-Präparate GmbH**  
(Reinfeld, Germany)

**Medical & Biological Laboratories Co., Ltd.**  
(Nagoya, Japan)

**Medipan Diagnostika GmbH**  
(Selchow, Germany)

**ORGENTEC Diagnostika GmbH**  
(Mainz, Germany)

**Pharmacia Diagnostics**  
(Freiburg, Germany)

**The Binding Site GmbH**  
(Schwetzingen, Germany)

**We thank these companies for helping to make this  
symposium successful.**



ANA

ANCA

Celiac **New**


CCP **New**



## Precision

for really accurate results


- *standardised conditions*
- *high reproducibility*



## Simplicity

ease of use

- *predefined tests*
- *one curve for all*



## Flexibility

to fit in with your lab

- *allows to combine tests for connective tissue diseases, vasculitides and celiac disease and RA*



## Automation

increased efficiency

- *full walk away operation*
- *results in 2,5 hours*